Welcome to our dedicated page for Brainstorm Cell Therapeutics I SEC filings (Ticker: BCLI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading BrainStorm Cell Therapeutics’ filings can feel like navigating a lab notebook—dense clinical data, pages of FDA correspondence, and detailed CMC tables. If you need to locate ALS trial endpoints or understand financing for the NurOwn® platform quickly, you’re not alone.
Stock Titan solves the problem. Our AI-powered summaries turn a 300-page BrainStorm Cell Therapeutics annual report 10-K simplified into digestible insights in minutes. Get real-time alerts the moment a BrainStorm Cell Therapeutics 8-K material events explained hits EDGAR or when a BrainStorm Cell Therapeutics Form 4 insider transactions real-time shows an executive stock purchase. We cover every filing type—10-Q, S-3, DEF 14A, 13D—so you never miss material disclosures.
Here’s what investors discover on this page:
- Pipeline progress hidden in the BrainStorm Cell Therapeutics quarterly earnings report 10-Q filing
- Cash runway and partnership milestones clarified in the 10-K
- Executive sentiment via BrainStorm Cell Therapeutics insider trading Form 4 transactions
- Board pay details inside the BrainStorm Cell Therapeutics proxy statement executive compensation
- Regulatory updates decoded in every 8-K
Want context rather than jargon? Our platform offers “understanding BrainStorm Cell Therapeutics SEC documents with AI” notes beside each section, plus instant charts for “BrainStorm Cell Therapeutics earnings report filing analysis.” Whether you’re reviewing CMC expenditures, monitoring BrainStorm Cell Therapeutics executive stock transactions Form 4, or benchmarking trial costs, you’ll find the data—and the plain-English explanation—right here.
Brainstorm Cell Therapeutics Inc. (Nasdaq: BCLI) has filed a Form S-3 shelf registration statement dated June 25, 2025. The filing registers up to 2,762,766 shares of common stock that may be resold from time to time by a single Selling Stockholder. The shares correspond to an equal number of common stock purchase warrants (designated “Inducement Warrants”) issued in a private placement on April 1, 2025. These warrants carry a cash exercise price of $1.19 per share, marginally below the June 24, 2025 closing price of $1.23.
The company itself will not sell shares nor receive proceeds from any secondary sales. It will, however, receive up to $3.29 million of gross proceeds if the Selling Stockholder elects to exercise all warrants in cash. Management states that any such proceeds would be used for working capital and general corporate purposes.
Key structural details include: (i) filing made under Rule 415 allowing continuous or delayed resales; (ii) BCLI is classified as a non-accelerated filer and smaller reporting company; (iii) no automatic effectiveness—statement will become effective only upon SEC approval; and (iv) no additional securities beyond those underlying the Inducement Warrants are being registered.
Potential investor considerations appear in the prospectus: dilution risk from warrant conversion, possible market overhang from discretionary resale by the Selling Stockholder, and limited capital inflow tied solely to warrant exercise. The prospectus addresses standard sections such as Risk Factors, Plan of Distribution, and Use of Proceeds but does not include financial statements or earnings data in this portion of the filing.
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) filed a Form 8-K summarizing the results of its June 25, 2025 virtual Annual Meeting of Stockholders. Shareholders approved Amendment No. 5 to both the 2014 Stock Incentive Plan and the 2014 Global Share Option Plan, expanding the shared equity pool by 2,000,000 shares to a total of 2,906,666 shares. Company officers and directors remain eligible to receive awards under the enlarged pool.
All seven director nominees—Dr. Irit Arbel, Dr. Menghisteab Bairu, Dr. Jacob Frenkel, Nir Naor, Dr. Anthony Polverino, Uri Yablonka and Dr. Stacy Lindborg—were re-elected, with votes “FOR” ranging from 958,146 to 1,055,967 and 2,556,446 broker non-votes on each slate. Shareholders also ratified Deloitte-affiliate Brightman Almagor Zohar & Co. as independent auditor for FY-2025 (3,346,891 “FOR” versus 315,162 “AGAINST”).
In addition, investors approved (i) Nasdaq Rule 5635(d) clearance to issue shares underlying a Common Warrant potentially exceeding 20% of current outstanding shares (874,965 “FOR”) and (ii) the aforementioned share-reserve increase (758,668 “FOR”, 362,809 “AGAINST”). No financial statements were presented; the filing is limited to governance and equity-compensation matters. The new equity authorizations could be dilutive if fully exercised, but they provide the company with added flexibility to reward personnel and fund future growth initiatives.
FAQ
What is the current stock price of Brainstorm Cell Therapeutics I (BCLI)?
What is the market cap of Brainstorm Cell Therapeutics I (BCLI)?
What is the main focus of BrainStorm Cell Therapeutics?
What is the NurOwn platform?
How does BrainStorm generate its therapeutic products?
What distinguishes BrainStorm in the competitive biotechnology landscape?
What role do clinical trials play in BrainStorm’s strategy?
How does BrainStorm address regulatory challenges?
What are the key advantages of using autologous cell therapy?
How does BrainStorm maintain its competitive edge?
